tablets Atoris are shown for:

• prevention of cardiovascular diseases;
• reduction of risk of developing of a myocardial infarction;
• reduction of risk of developing of a stroke;
• reduction of risk of holding procedures of revascularization and stenocardia.
• reduction of risk of developing of a non-lethal myocardial infarction;
• reduction of risk of developing of a lethal and non-lethal stroke;
• reduction of risk of hospitalization in connection with stagnant heart failure.

Structure

Active ingredient: 1 tablet, coated 10 mg, 20 mg, 40 mg of an atorvastatin in the form of an atorvastatin of calcium;

Excipients:

10 mg, 20 mg povidone, sodium lauryl sulfate, calcium carbonate, cellulose microcrystalline, lactose, sodium of a kroskarmelloz, magnesium stearate;

Cover: talc, polyvinyl alcohol, macrogoal 3000, titan dioxide (E 171);

40 mg povidone, sodium lauryl sulfate, calcium carbonate, cellulose microcrystalline, lactose, sodium of a kroskarmelloz, krospovidon, magnesium stearate;

Cover: gipromelloza, macrogoal 400, titan dioxide (E 171).

Contraindication

Active disease of a liver which can include steady increase in activity of hepatic transaminases of not clear etiology.

Hypersensitivity to any of components of this medicine.

Route of administration

Prior to the Atoris® medicament treatment the level of a hypercholesterolemia and to control observance of the corresponding diet, physical activities, degrowth of a body at patients with obesity and treatments of other main medical problems of patients. At administration of medicament of Atoris® the patient has to adhere to the standard diet reducing cholesterol level.

Feature of use

Pregnant

It is contraindicated.

Children

Since 10 years.

Drivers

is Carried out by very insignificant influence on speed of response at control of motor transport or work with other mechanisms.

Overdose

Specific treatment of overdose of an atorvastatin. In case of overdose of the patient it is necessary to treat symptomatically and if necessary to take the supporting measures. For high extent of linking of medicament with proteins of plasma should not expect considerable strengthening of clearance of an atorvastatin by means of a hemodialysis.

Atorvastatin in general is well had by

.

treat undesirable reactions: thorax pain, face edema, fever, asthenia, muscle tension of a neck, weakness, photosensitization, generalized hypostases, indisposition, pyrexia, peripheral hypostases.

Interaction

Risk of development of a myopathy during treatment by statines increases in case of simultaneous use of derivatives of fibroyevy acid, lipidomodifikatsiyny doses of Niacinum, cyclosporine or powerful CYP inhibitors 3A4 (for example a klaritromitsina, inhibitors of HIV protease and an itrakonazol).

Grapefruit juice. Contains one or more components which inhibit CYP 3A4 and can increase concentration of an atorvastatin in blood plasma, especially at excess consumption of grapefruit juice (more than 1.2 liters a day).

Should avoid simultaneous use of an atorvastatin and cyclosporine.

to Store

in original packing at a temperature not above 25 °C.

to Store

out of children's reach.

Expiration date - 2 years.